e-Article
Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
Document Type
Article
Author
Source
In European Journal of Obstetrics and Gynecology February 2018 221:46-51
Subject
Language
ISSN
0301-2115